| FLT3-ITD Targeted Therapy in Fit AML Patients (NCT07425808) | European Organisation for Research and Treatment of Cancer - EORTC | 2026-12-01 |
| Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets (NCT07234877) | European Organisation for Research and Treatment of Cancer - EORTC | 2026-11-01 |
| Eortc MoBilE Device (EMBED) (NCT07711080) | European Organisation for Research and Treatment of Cancer - EORTC | 2026-09-01 |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer (NCT06783348) | European Organisation for Research and Treatment of Cancer - EORTC | 2026-04-07 |
| Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment (NCT06978062) | European Organisation for Research and Treatment of Cancer - EORTC | 2026-02-20 |
| Vorasidenib Maintenance for IDH Mutant Astrocytoma (NCT06809322) | European Organisation for Research and Treatment of Cancer - EORTC | 2026-01-16 |
| Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study (NCT06990061) | European Organisation for Research and Treatment of Cancer - EORTC | 2025-12-01 |
| Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (NCT05815927) | European Organisation for Research and Treatment of Cancer - EORTC | 2025-05-23 |
| Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors (NCT05974774) | European Organisation for Research and Treatment of Cancer - EORTC | 2025-05-23 |
| OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT) (NCT06462963) | European Organisation for Research and Treatment of Cancer - EORTC | 2025-04-15 |
| 177Lu-DOTATATE for Recurrent Meningioma (NCT06326190) | European Organisation for Research and Treatment of Cancer - EORTC | 2025-03-10 |
| Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer (NCT06310369) | European Organisation for Research and Treatment of Cancer - EORTC | 2025-03-01 |
| Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC (NCT06219317) | European Organisation for Research and Treatment of Cancer - EORTC | 2025-01-14 |
| Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer (NCT06407401) | European Organisation for Research and Treatment of Cancer - EORTC | 2024-12-01 |
| Adjuvant Tebentafusp in High Risk Ocular Melanoma (NCT06246149) | European Organisation for Research and Treatment of Cancer - EORTC | 2024-11-11 |
| Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study (NCT06347185) | European Organisation for Research and Treatment of Cancer - EORTC | 2024-09-01 |
| Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study (NCT05904119) | European Organisation for Research and Treatment of Cancer - EORTC | 2024-03-15 |
| Chemo-free BRCA-targeted Neoadjuvant Strategy (NCT05209529) | European Organisation for Research and Treatment of Cancer - EORTC | 2024-02-01 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (NCT05512364) | European Organisation for Research and Treatment of Cancer - EORTC | 2023-12-15 |
| Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT05724602) | European Organisation for Research and Treatment of Cancer - EORTC | 2023-11-15 |
| Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification (NCT05259605) | European Organisation for Research and Treatment of Cancer - EORTC | 2023-03-21 |
| Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma (NCT04128072) | European Organisation for Research and Treatment of Cancer - EORTC | 2023-03-07 |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (NCT04402073) | European Organisation for Research and Treatment of Cancer - EORTC | 2022-11-11 |
| PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) (NCT04790253) | European Organisation for Research and Treatment of Cancer - EORTC | 2022-10-27 |
| Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma (NCT04933942) | European Organisation for Research and Treatment of Cancer - EORTC | 2022-09-13 |
| Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer (NCT04796454) | European Organisation for Research and Treatment of Cancer - EORTC | 2022-05-01 |
| A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma (NCT04780464) | European Organisation for Research and Treatment of Cancer - EORTC | 2022-04-11 |
| REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (NCT04218825) | European Organisation for Research and Treatment of Cancer - EORTC | 2022-03-29 |
| Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (NCT04498767) | European Organisation for Research and Treatment of Cancer - EORTC | 2021-06-10 |
| Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (NCT03673735) | European Organisation for Research and Treatment of Cancer - EORTC | 2021-06-01 |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (NCT04031677) | European Organisation for Research and Treatment of Cancer - EORTC | 2021-01-20 |
| Study of Photopheresis in the Treatment of Erythrodermic MF and SS (NCT03563040) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-12-01 |
| Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (NCT04127110) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-11-17 |
| Follow-up in Early and Locally Advanced Breast Cancer Patients (NCT03859453) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-10-14 |
| Dissecting the Pathways of Therapy Resistance in Early Breast Cancer (NCT04995575) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-07-08 |
| Long-term Surival of GIST Patients ≥ 10 Years on Imatinib (NCT04097093) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-06-01 |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome (NCT04065165) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-04-01 |
| Trial in Low Grade Glioma Patients: Wait or Treat (NCT03763422) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-03-16 |
| Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer (NCT03488810) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-03-10 |
| Pembrolizumab in Biliary Tract Cancer (NCT03260712) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-01-07 |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (NCT03818997) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-12-01 |
| Reduced Dose-density of Denosumab for Unresectable GCTB (NCT03620149) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-09-26 |
| Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (NCT03517137) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-08-01 |
| Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (NCT03443856) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-07-17 |
| E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe (NCT03818503) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-06-24 |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer (NCT03609047) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-06-14 |
| Follow-up in Gynecological Cancer Survivors (NCT03515993) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-02-21 |
| Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (NCT03437200) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-01-17 |
| Synergism of Immunomodulation and Tumor Ablation (NCT03101475) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-11-23 |
| Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (NCT03319316) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-11-01 |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (NCT03235245) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-10-30 |
| PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) (NCT03357224) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-09-24 |
| A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (NCT03345095) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-07-26 |
| Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma. (NCT03224104) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-06-12 |
| Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NCT03134118) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-04-11 |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma (NCT02863055) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-02-04 |
| Imaging Biomarker in Cancer Drug Induced ILD (NCT03294746) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-01-01 |
| Pembrolizumab in Untreated Extensive SCLC (NCT02580994) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-12-08 |
| ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer (NCT02972060) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-12-01 |
| Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma (NCT02984410) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-11-27 |
| Biomarker-based Study in R/M SCCHN (NCT03088059) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-11-16 |
| Trabectedin Maintenance Post 1st-line in STS (NCT02929394) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-11-07 |
| Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) (NCT02856893) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-10-10 |
| Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (NCT02799706) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-09-25 |
| Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma (NCT02808247) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-07-07 |
| SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access (NCT02834884) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-05-03 |
| Ph II CABOGIST in GIST (NCT02216578) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-02-02 |
| Lenvatinib in Second Line Endometrial Carcinoma (NCT03005015) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-01-01 |
| Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer (NCT02659384) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-12-23 |
| Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) (NCT02856867) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-12-01 |
| Diffusion-Weighted MRI for Liver Metastasis (NCT02781935) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-11-01 |
| Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM (NCT02436733) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-09-20 |
| SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access (NCT02307604) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-05-01 |
| A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer (NCT02501278) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-05-01 |
| Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (NCT02470065) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-01-01 |
| Phase III Radium 223 mCRPC-PEACE III (NCT02194842) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-10-01 |
| Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo (NCT02273271) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-10-01 |
| Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (NCT01969578) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-09-24 |
| LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC (NCT01795521) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-08-01 |
| Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (NCT02205047) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-07-15 |
| Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma (NCT03770468) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-07-05 |
| Trabectedin for Recurrent Grade II/III Meningioma (NCT02234050) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-07-01 |
| SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access (NCT02214134) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-05-22 |
| A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program (NCT02218801) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-05-01 |
| IRCI Gynae Sarcomas, High Grade Uterine Sarcoma (NCT01979393) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-02-02 |
| Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer (NCT02355353) | European Organisation for Research and Treatment of Cancer - EORTC | 2015-02-01 |
| "InDACtion" vs "3+7" Induction in AML (NCT02172872) | European Organisation for Research and Treatment of Cancer - EORTC | 2014-11-28 |
| Cancer in Nursing Home Residents (NCT01910376) | European Organisation for Research and Treatment of Cancer - EORTC | 2014-10-01 |
| Ph II Cabazitaxel DD Liposarcoma (NCT01913652) | European Organisation for Research and Treatment of Cancer - EORTC | 2014-10-01 |
| AF CRT +/- Nimorazole in HNSCC (NCT01880359) | European Organisation for Research and Treatment of Cancer - EORTC | 2014-07-25 |
| Nintedanib(BIBF1120) in Thyroid Cancer (NCT01788982) | European Organisation for Research and Treatment of Cancer - EORTC | 2014-05-01 |
| TAK-700 in Castration Resistant Prostate Cancer (NCT01658527) | European Organisation for Research and Treatment of Cancer - EORTC | 2014-01-01 |
| Screening Platform for Clinical Trials in Advanced Colorectal Cancer (NCT01723969) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-09-01 |
| Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study (NCT01838577) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-09-01 |
| Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (NCT01508000) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-06-01 |
| Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (NCT01597414) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-06-01 |
| Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) (NCT01652261) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-05-01 |
| Colorectal Cancer (CRC) Cetuximab Elderly Frail (NCT01522612) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-04-01 |
| Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (NCT01548677) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-04-01 |
| Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases (NCT01646554) | European Organisation for Research and Treatment of Cancer - EORTC | 2012-12-01 |